Present Aids Vaccine That Prevents 30% of Infections
It will take several years to research for adoption and use, but after 20 years of unsuccessful trials, an AIDS vaccine has proved able to prevent 30% of new infections. The vaccine is purely defensive, not serve as a treatment in people already infected.
Thai and American scientists had a few days before the public the scientific breakthrough that opens the door to hope for 33 million people around the world (UN estimate of AIDS patients in 2007).
AIDS vaccine is actually a mixture of two old who had failed vaccines separately: Sanofi Pasteur's ALVAC-the-world leader in vaccines based on avian canary pox virus, and AIDSVAX of VaxGen, a small company San Francisco later acquired by a nonprofit organization, Global Solutions for Infectious Diseases. Scientists do not know why it has worked a mixture of both, called RV144.
The trial, at a cost of $ 420 million – the Pentagon has financed 105 million – has lasted three years in Thailand, with 16 400 heterosexual volunteers and do not belong to any particular risk group. Between half placebo have been 74 new infections of HIV, only 51 in the half that received the drug. The vaccine against AIDS, therefore, prevents 31% of new infections.
